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Viral Infections after Kidney 
Transplantation: CMV and BK
Večerić-Haler Željka and Kojc Nika
Abstract
Opportunistic infections commonly occur during the first 6 months after kidney 
transplant, including cytomegalovirus (CMV) and polyomaviruses. Viral pathogens 
such as CMV and polyomaviruses, JC or BK virus (BKV), are able to replicate in the 
kidney and/or cause systemic disease, and symptomatic infection with these agents 
can be associated with significant morbidity and mortality in immunocompromised 
host. While BK virus usually replicates in kidney transplant causing BK virus 
nephropathy (BKN) with characteristic decoy cells in the urine, CMV infection 
more often leads to systemic infection involving the gastrointestinal tract (GIT), 
lungs, or liver and can only sporadically be detected in renal transplant. In both 
cases, the disease is most often due to reactivation of a latent virus. Prevention and 
early treatment of posttransplant infection are therefore crucial with kidney trans-
plant recipients. Since BKV viruria and viremia can be seen without renal injury 
and viral nephropathy, a diagnosis of BKN must be confirmed by renal biopsy. To 
date, preemptive treatment is the best strategy for CMV infection, while no avail-
able standard therapy, except for reduction of immunosuppression, is available for 
BKV infection.
Keywords: CMV, BK, cytomegalovirus, polyomavirus, viral infections,  
kidney transplantation
1. Introduction
CMV and polyomavirus infection is common in the human population and 
mainly remains asymptomatic through the life of healthy individuals. However, in 
immunocompromised individuals, such as kidney transplant recipients (KTRs), it 
can be associated with various complications, including direct systemic effects of 
viral infection, bacterial or fungal superinfection, viral infection of the transplanted 
kidney, and acute and chronic rejection, which consequently diminish patient and 
graft survival. Current preventive strategies in KTRs include preemptive therapy 
with valganciclovir or intravenous ganciclovir and universal prophylaxis with 
antivirals after kidney transplantation and for 1–3 months after treatment with 
antilymphocyte antibodies. Strategies to control established virus infection include 
decreasing immunosuppression, adding antivirals, and a combination of both [1–3].
BK virus nephropathy is the most common manifestation of BKV reactivation 
after renal transplantation, leading to loss of renal grafts in approximately 43% 
of patients. BKV viruria and viremia can be seen without renal injury and viral 
nephropathy, so renal biopsy remains the gold standard for definite BKN diagnosis. 
Therapeutic strategies of BKN management are still very limited, so screening 
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protocols in order to detect early BK reactivation are important. BKN might be suc-
cessfully managed with a reduction of baseline immunosuppression but is poten-
tially harmful since it may be associated with increased risk of rejection [4–6].
2. CMV infection
CMV is a double-DNA virus of the herpesvirus family transmitted via saliva, 
body fluids, or tissue. There are various, species-specific strains of cytomegalovirus 
[7]. Seroprevalence ranges between 30 and 70% in Europe and North America. 
Following primary infection, CMV establishes latency in myeloid progenitor cells 
and can be transiently reactivated in a healthy host without causing disease, similar 
to polyomaviruses. However, CMV reactivates frequently and causes disease in 
KTRs in the setting of immunocompromised, typically in the first 2–3 months after 
transplantation [8, 9]. CMV viremia in the 1–6 months after transplantation is 
significantly more frequent in KTRs older than 65 years.
Reinfection (primary infection with a different human strain) can also occur [10].
CMV infection is the most common infectious disease following solid organ 
transplantation, including kidney [1, 3].
In addition to the direct effects of viral infection, CMV infection and disease 
have been associated with acute and chronic rejection and diminished patient and 
graft survival [2]. The transplanted kidney itself is only rarely affected by CMV 
reactivation.
The greatest recognized risk factor for CMV disease is a serological mismatch 
between the donor and the recipient (the recipient is CMV IgG seronegative and the 
donor is CMV IgG seropositive: D+/R−). Furthermore, CMV D+/R+ and CMV D−/R+  
transplantations are of intermediate risk for the development of disease, and CMV 
D−/R− transplantation is considered as low risk (<5% incidence) [11, 12].
2.1 Definition
After the resolution of primary infection, CMV establishes latent infection. 
CMV can present in KTRs as either active CMV infection or CMV disease [9, 13].
Primary CMV infection: CMV infection in a person who was previously CMV 
seronegative (negative IgM and IgG CMV antibodies).
Latent CMV infection: after the resolution of acute (or primary) infection, CMV 
establishes latent infection. Patients who are CMV seropositive (IgG CMV anti-
bodies) have latent infection. Secondary, symptomatic disease may present later, 
reflecting either reactivation of latent CMV or, less commonly, reinfection with a 
novel exogenous strain.
Active CMV infection is defined by CMV virus replication in plasma (viral load, 
viremia). CMV infection can be asymptomatic or symptomatic. The degree of 
immunosuppression in KTRs may determine progress to CMV disease.
CMV disease is defined as the presence of detectable CMV in a clinical specimen 
accompanied by other clinical manifestations. CMV disease may manifest as either 
CMV syndrome or tissue-invasive CMV disease [3].
2.2 Clinical features of CMV disease
2.2.1 CMV syndrome
For a determination of CMV syndrome, CMV in plasma (quantitative PCR CMV 
DNA (PCR)) and the presence of at least one of the following symptoms and signs 
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of disease are necessary: fever ≥38°C, general signs (malaise, myalgia, arthralgias), 
leukopenia (≤3.5 × 109/L), atypical lymphocytosis (≥5%), and thrombocytopenia 
(≤100 × 109/L). In a case of suspected CMV nephritis in KTRs, kidney graft rejec-
tion should always be ruled out [3].
2.2.2 Tissue-invasive disease
In a case of tissue-invasive CMV disease, evidence of particular tissue/organ 
involvement (hepatitis, colitis, pancreatitis, pneumonitis, nephritis, cystitis, etc.) 
is based on clinical symptoms and signs associated with a particular organ, posi-
tive quantitative PCR CMV DNA in plasma, and, in particular, on the presence of 
CMV in a given organ or tissue (detected by methods of isolation, histopathology, 
immunohistochemistry, or hybridization in situ). CMV invasive disease can be 
most frequently detected in the intestine (40%) followed by the liver (20%), lungs 
(10%), kidneys (5%), and eyes/brain (1%) [8]. For CMV encephalitis, it is suf-
ficient to prove the presence of CMV in the liquor (PCR) and for CMV pneumonitis 
in bronchoalveolar flushing (PCR).
In suspected CMV retinitis, ophthalmological examination is sufficient for the 
diagnosis. In patients with tissue-invasive disease (particularly in CMV infection 
of the central nervous system, chorioretinitis, and in CMV infection of the gut), 
CMV viremia may be absent, so some more invasive diagnostics (lumbar puncture, 
sigmoidoscopy/colonoscopy) must be proceeded in case of clinical suspicion [14].
2.3 Diagnosis
In KTRs who present with signs and symptoms suspicious for CMV disease, 
laboratory confirmation is required to establish the diagnosis. A biopsy with 
histopathologic examination of tissue is occasionally necessary to diagnose tissue-
invasive CMV disease.
A diagnosis of CMV infection is most often confirmed with nucleic acid testing 
using polymerase chain reaction (PCR) for the detection of CMV DNA. PCR is 
primarily used to evaluate blood, cerebrospinal fluid, and ocular or vitreous fluid, 
although various clinical specimens can be subjected to this assay.
Among other tests to detect CMV, the demonstration of CMV p65 antigen in 
circulating polymorphonuclear leukocytes in the buffy coat has been used both to 
monitor response to therapy and as a guide to starting treatment in some centers. 
Traditional viral cultures are rarely used to diagnose CMV [15].
The most common serologic tests that detect CMV antibodies (IgM and IgG 
antibody to CMV) are based on enzyme-linked immunosorbent assay (ELISA). 
A positive test for CMV IgG indicates that a person was infected with CMV at 
some time during their life. The presence of CMV IgM cannot be used by itself to 
diagnose primary CMV infection because IgM can persist for months after primary 
infection and because IgM can be positive in reactivated CMV infections [16].
On occasion histopathological confirmation of CMV disease is necessary to 
prove CMV organ-specific dysfunction.
2.4 Histological features of tissue-invasive disease
Productive CMV infection in the tissue is characterized by a cytopathic viral 
effect in the biopsy specimen of parenchymal organs and the presence of CMV-
positive cells by immunohistochemistry or by in situ hybridization with antibody 
directed against the immediate early antigen. Additionally, CMV virions may be 
detected by electron microscopy [17].
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In daily practice, CMV reactivation is most frequently detected in GIT biopsies, 
including the colon and stomach (Figure 1). In contrast to polyomaviruses, CMV 
invasive disease is only sporadically detected in transplanted kidney [18, 19].  
Histological features of CMV replication-related lesions in native kidneys are 
similar to those in renal transplants [20, 21].
2.4.1 CMV disease in kidneys
CMV nephritis is characterized by virally induced direct tissue injury and by 
biopsy-proven cytopathic changes. Cytopathic changes are typically focal and 
detected in tubular epithelial cells or endothelial cells (Figure 2).
Three patterns have been observed: pattern I with large intranuclear inclusions in 
tubular epithelial cells with interstitial nephritis, pattern II with central large eosinophilic 
intranuclear inclusions in endothelial cells, and rarely, CMV infection may occur as acute 
glomerulonephritis (pattern III) [18]. CMV infection may also affect podocytes.
In the predominant tubular involvement, tubular CMV infection is usually 
accompanied by variable interstitial inflammation. In addition, monocyte inclu-
sions in the interstitial infiltrate may be observed. Occasionally, a dense nodular 
mononuclear and plasma cell infiltrate is present in the interstitium, sometimes 
reminiscent of granuloma. Focal necrosis and microabscesses are rarely observed. 
Prominent tubulitis reminiscent of T-cell-mediated rejection characteristic in 
BKN is absent.
The involvement of endothelial cells is characterized by a central large eosino-
philic intranuclear inclusions surrounded by a circumferential halo resembling 
a typical owl’s eye. Glomerular and peritubular capillary endothelial cells may 
Figure 1. 
CMV gastritis with focal active and chronic inflammation (A, Trichrome stain, 100x). Immunohistochemical 
stain against CMV antigen shows numerous CMV-positive cells (B, CMV, 100x).
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be infected. In some nuclei, a smudgy-appearing intranuclear inclusion can be 
detected. In the cytoplasm of viral-infected cells, there are sometimes small 
basophilic cytoplasmic viral inclusions. When endothelial cells are predominantly 
CMV-infected cells, tubular epithelium tends to be spared. In such cases, interstitial 
inflammation is not prominent [18].
Immunofluorescence with a standard panel of antibodies is usually unremark-
able, only rarely are scarce glomerular IgG deposits detected [20–22].
CMV nephritis may be associated with concurrent antibody- and T-cell-
mediated rejection in 30% of cases [22]. In contrast to polyomavirus, CMV often 
replicates in endothelial and inflammatory cells. Distinction between infection-
driven inflammation and rejection may be difficult.
Immunomodulation of the immune response might be the most important indi-
rect effect of CMV infection on kidney graft, rather than direct CMV nephritis. 
Figure 2. 
CMV nephritis in transplanted kidney: focal interstitial inflammation and cytopathic changes in scarce tubular 
epithelial cells (A, hematoxylin eosin (HE), 200x). CMV inclusions are confirmed by immunohistochemistry 
(B, CMV, 400x). Courtesy of Danica Galešič Ljubanović and Petar Šenjug.
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It is considered to promote rejection episodes by stimulating a T-cell-mediated 
response. Reinke reported that 85% of patients with late-acute renal allograft 
rejection with otherwise symptomless CMV infection responded to ganciclovir 
therapy, which emphasized the indirect role of CMV infection on graft function 
[23]. CMV infection does not activate classic complement pathway nor trigger the 
deposition of complement factor C4d along peritubular capillaries; in the case of 
positive C4d deposition, concurrent ABMR should be considered.
2.4.2 CMV disease in gastrointestinal tract
Cytomegalovirus infection of the gastrointestinal tract is the most common 
manifestation of tissue-invasive CMV disease and is a significant cause of morbidity 
and mortality in the solid organ transplantation recipients. Patients usually present 
with esophagitis, colitis, and hepatitis; however, infection can occur anywhere in 
the gastrointestinal tract [17, 24, 25].
Mucosal ulceration was the most common endoscopic finding present in 75% 
of cases (Figure 3). Other endoscopic features include mucosal edema, hyperemia, 
and nodularity. In a renal transplant patient, cytomegalovirus infection may rarely 
present as a localized disease, such as inflammatory polyps [26].
Two histologic patterns of GIT tissue injury have been described. In the first 
form, viral inclusions are typically found in the glandular epithelium with little 
associated tissue reaction (Figure 4). In the second form, CMV inclusions are found 
in swollen endothelial and stromal cells, especially in areas of ulceration. Typically, 
mucosal erosion, ulceration, hemorrhage, necrosis, perforation, and/or fistula 
formation can be detected. CMV colitis is characterized by uneven inflammation in 
the lamina propria, with active changes and ulcers with abundant purulent exudate 
(Figures 3 and 5) [24].
In contrast to other organs, CMV infection in the colon does not always produce 
the diagnostic large cells with viral inclusions with owl’s eye appearance. Rather, the 
infected cells can be smaller, up to twice as big as their normal counterparts, and 
have small basophilic inclusions, often with no characteristic clear halo. They have 
been called “atypical inclusions” [27].
Diagnosis is usually by histopathology with immunohistochemistry or viral 
culture of tissue specimens; molecular assays such as quantitative PCR also often 
have a role (Figures 4 and 5).
However, there is little consensus on the specificity of PCR [28–30]. Since CMV 
typically produces latent infection residing in leukocytes, concern has been raised 
that positive PCR might therefore not necessarily reflect active disease in the colon 
but only latent infection. The use of colon tissue alone was therefore not widely 
considered to provide definitive proof of CMV colitis [13]. Zidar et al. observed 
good correlation among the density of positive cells by immunohistochemistry, the 
Figure 3. 
Mucosal ulcerations in CMV colitis of kidney transplant recipient are common endoscopic findings.
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Figure 4. 
CMV gastritis.  Intranuclear inclusion (arrow) in foveolar gastric cell (A) and in endothelial cell (arrow) 
of a capillary in the lamina propria (both Thricrome stain, 600x). CMV positive Intranuclear inclusions by 
immunohistochemistry (C, CMV, 600x). Scarce mucosal ulcerations seen on gastroscopy (D).
Figure 5. 
CMV colitis in kidney transplant recipient. Focal active colitis with erosions (A, Trichrome stain, 100x). There 
was only one positive CMV cell by immunohistochemistry (CMV, 400x).
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morphology, and the number of viral copies by qPCR in IBD patients. Both immu-
nohistochemistry and qPCR can therefore be successfully used for diagnosing CMV 
reactivation, at least in CMV reactivation in patients with IBD. The optimal sites 
for endoscopic biopsies to obtain specimens with the highest values of CMV are the 
base and the edge of ulcers [28, 31].
2.5 Prevention of CMV disease
CMV can be prevented in two ways: by prophylaxis and by preemptive treat-
ment. Both options are effective for preventing CMV disease [32–34].
2.5.1 CMV prophylaxis therapy
CMV prophylaxis is widely used in the transplantation setting and has been asso-
ciated with reductions in CMV disease, mortality, and graft rejection. Prophylaxis 
refers to the administration of antiviral drugs to all patients (universal prophylaxis) 
or to a subgroup of patients at higher risk of viral replication (specific prophylaxis) 
for a predetermined period of time. In KTRs, prophylaxis therapy aims to prevent 
CMV infection and, consequently, CMV-associated disease. According to current 
guidelines, universal prophylaxis is recommended in patients with high risk (i.e., 
those who have D+/R− CMV IgG or who have received T-cell depletion for induction 
prior to transplantation). Antiviral drug treatment should begin immediately after 
transplantation or after the use of antilymphocyte antibodies. Patients with low to 
intermediate risk can undergo preemptive treatment instead of prophylaxis [35].
Until recently, the emphasis on prophylaxis with prophylactic agents focused 
on early disease occurring in high-risk patients, with the duration of prophylaxis 
typically no longer than 3 months. Although early-onset CMV infection was usually 
sufficiently controlled, the reported incidence of delayed-onset CMV infection 
following the completion of a 3-month course of preventive therapy was high, and, 
consequently, prophylactic therapy in most centers was extended to 6 months in the 
group of KTRs at most risk (D+/R−) [36, 37].
Several medications are available: acyclovir, valacyclovir, intravenous ganciclo-
vir, oral ganciclovir, and valganciclovir. Ganciclovir takes precedence over acyclo-
vir. In a clinical setting, the most commonly used medication for prophylaxis is oral 
valganciclovir with dose adjustment according to kidney function [38].
The prophylaxis should be initiated immediately after transplantation. The 
decision on the duration of prophylaxis depends on the CMV serostatus of the 
donor (D) and recipient (R), of the organ transplant, and the degree of immune 
deficiency in the transplant recipient.
2.5.1.1 Prophylaxis in D+/R− recipient
In D+/R−, prophylaxis should last for 3–6 months. According to recent research, 
many transplant centers are opting for a 6-month prophylaxis, which has been asso-
ciated with a significant decrease in the incidence of late CMV disease, compared 
to 3-month prophylaxis. Valganciclovir at a dosage of 900 mg orally once daily with 
the dose adjusted for renal function is used in most centers for a period of 6 months 
following transplantation.
2.5.1.2 Prophylaxis in D+/R+ or D−/R+
In D+/R+ or D−/R+, prophylaxis should last for 3 months. Extension to 
6 months is suggested for KTRs who have received antilymphocyte antibody 
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induction. Valganciclovir at 900 mg orally once daily for 3 months following trans-
plantation, with the dose adjusted for renal function, is the standard prophylactic 
therapy in most centers.
2.5.1.3 Prophylaxis in D−/R−
There is little risk of CMV infection in these patients. Precautions for transfu-
sion of blood and blood products of CMV-positive donors are required [35].
2.5.2  Additional considerations in the prevention of CMV in kidney transplant 
recipients
2.5.2.1 CMV matching
Theoretically, a method of minimizing the risk of CMV infection would be 
to avoid transplantation of a seropositive organ into a seronegative recipient. 
Historically, before the advent of antiviral prophylaxis, many units avoided trans-
planting CMV-positive solid organs into CMV-negative recipients. However, given 
the shortage of donor organs, such an approach is difficult to practice in these 
settings.
One area in which CMV matching remains relevant is in the elective use of blood 
products. Where it is known that both donor and recipient are seronegative for 
CMV, leukodepleted blood and blood products are available and should be used to 
minimize the risk of primary infection [39].
2.5.2.2 Passive immunoprophylaxis
Passive immunoprophylaxis has been explored in solid organ transplantation in 
a number of randomized trials, whereby hyperimmune globulin provided signifi-
cant overall protection from severe disease, with a reduced rate of CMV disease 
to approximately half of that seen in the placebo groups. Intravenous treatment is 
generally less convenient for the patient and health-care provider and carries the 
theoretical risk of transmitting blood-borne viruses [39].
2.5.3 Preemptive therapy
With quantitative monitoring of CMV DNA in plasma (viral load, viremia) 
once a week (sometimes twice a week), CMV viremia can be detected before the 
occurrence of symptomatic infection. However, the exact cutoff point of plasma 
CMV concentration to initiate preemptive treatment (from a few hundred to several 
thousand copies of CMV DNA in 1 ml of plasma) is not known. The decision to 
initiate preemptive treatment is therefore individual and depends mainly on the 
degree and duration of immunosuppression [40].
The benefits of this type of strategy are that fewer patients are exposed to anti-
virals and for a shorter period of time (fewer side effects, fewer interactions with 
other medicines, lower costs).
Intravenous ganciclovir (5 mg/kg every 12 h or a dose adjusted to creatinine 
clearance) is used for preemptive treatment in a patient with a high viral load 
(>50,000 copies of CMV DNA in 1 ml of plasma), in severe renal impairment, 
and in pediatric patients; otherwise, valganciclovir (900 mg every 12 h, or a dose 
adjusted to creatinine clearance) is recommended. If there is no CMV disease, the 
CMV viremia is checked for the first time after 7–10 days of preemptive treatment, 
afterward being monitored every 7–10 days. It is recommended to continue with 
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preemptive therapy until two negative results of quantitative plasma PCR CMV 
DNA tests performed in a space of 7 days [40].
2.5.3.1 Guiding of preemptive therapy by measurement of CMV-specific T lymphocytes
The activity and concentration of CMV-specific lymphocytes in the blood have a 
decisive role in controlling CMV infection, especially in situations of increased risk 
of CMV reactivation or primary infection, such as after therapeutic use of antilym-
phocyte antibodies. The count of CMV-specific T lymphocytes allows a decision on 
preemptive treatment in a period when the viral load is still not critically increased.
Among the available methods, the most reliable predictor of viremia and disease 
is measurement of the blood concentration of T lymphocytes, which, after in vitro 
stimulation with CMV peptides, increasingly produce cytokines such as interferon 
gamma and interleukin 2. CMV-specific lymphocytes CD4 and CD8 are analyzed 
by the flow cytometry method (one of the most commonly used is a whole blood 
interferon gamma release assay QuantiFERON-CMV test marketed by an Australian 
company, Cellestis Inc., which measures the production of interferon gamma after 
stimulating the patient’s lymphocytes with CMV peptides) [41].
2.6 Treatment of CMV disease
Treatment is always indicated in case of active CMV infection (CMV viral 
syndrome) or in the presence of tissue-invasive CMV disease [42].
Intravenous ganciclovir is a gold standard for the treatment of CMV disease. 
In mild to moderate cases of the disease, oral valganciclovir was found to be non-
inferior to intravenous ganciclovir. However, due to limited evidence, severe disease 
should be treated with intravenous ganciclovir. Acyclovir and valacyclovir are not 
indicated for treatment. The use of foscarnet as a first-line therapy is limited by its 
toxicity (mainly nephrotoxicity) (Table 1).
Drug resistance should be suspected in patients with persistent viral repli-
cation and/or clinical progression after 2–3 weeks of treatment. Ganciclovir-
resistant CMV infection has been observed in 1–2% of kidney transplant 
recipients and is a result of the widespread use of antiviral prophylaxis and 
preemptive therapy. Drug resistance typically develops in CMV D+/R− patients 
and is also associated with high viral load, prolonged antiviral therapy, high level 
of immunosuppression (i.e., use of antilymphocyte antibodies), and suboptimal 
serum drug concentrations. Genotypic tests reveal characteristic viral mutants 
(UL97) associated with resistance [43].
Drug-resistant or refractory CMV disease occasionally responds to an increased 
dose of ganciclovir. In cases of genotypic resistance of CMV to ganciclovir, it is 
necessary to introduce combined treatment with ganciclovir and foscarnet (half or 
standard doses) or treat with foscarnet only [44].
The treatment should be continuous until viral eradication is achieved in two 
assays after a minimum of 2 weeks of induction treatment. Initial treatment with 
intravenous ganciclovir can be later replaced with oral valganciclovir. During the 
course of treatment, renal function must be promptly monitored. In most cases 
(especially in high viremia, a moderate to severe clinical course, ganciclovir resis-
tance), it is necessary to reduce immunosuppressive therapy (especially antimetab-
olites, i.e., azathioprine or mycophenolate). The same applies in cases of recurrent 
CMV infection/disease [35].
In the case of high-risk patients, some authors recommend secondary prophy-
laxis after completion of treatment, although no consensus has so far been achieved 
on this approach [35, 45].
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Drug Dosage Action Formulation Common side effects
Ganciclovir 5 mg/kg bw i.v.; adjusted to eGF
* Oral preparation has low 
bioavailability
Competitive inhibition of DNA 
synthesis catalyzed by the viral 
DNA polymerase
Leukopenia, thrombocytopenia, diarrhea, 
long-term reproductive toxicity
Valganciclovir 900 mg bd p.o.; adjusted to eGF Rapidly metabolized into active 
form (ganciclovir) in the intestinal 
wall and liver; same action as 
ganciclovir
Leukopenia, thrombocytopenia, anemia, 
gastrointestinal toxicity
Foscarnet 90 mg/kg bw bd i.v. or 60 mg/kg 
bw every 8 h; adjusted to eGF
Inhibits activity to the viral 
DNA polymerase by binding 
to the pyrophosphate binding 
site and blocking cleavage of 
pyrophosphate from the terminal 
nucleoside triphosphate added to 
the growing DNA chain
Nephrotoxicity, electrolyte disturbances, 
neurotoxicity
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Drug Dosage Action Formulation Common side effects
Cidofovir 5 mg/kg i.v. once a week for 2 
consecutive weeks. Following 
induction dose, 5 mg/kg i.v. once 
every 2 weeks administer with 
probenecid to decrease side 
effects to the kidney
After conversion to active 
form, cidofovir diphosphate 
competitively inhibits DNA 
polymerase
Nephrotoxicity, neutropenia, teratogenicity, 
carcinogenicity, nausea, vomiting
Maribavir To be determined Inhibits UL97 kinase and stops 
viral maturation and egress
Taste disturbance; inferior at preventing 
CMV disease
i.v., intravenous; p.o., peroral; eGF, estimated glomerular filtration.
Table 1. 
Drugs used in therapy of CMV disease.
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3. BK polyomavirus infection and disease in humans
Polyomaviruses are non-enveloped, double-stranded ubiquitous DNA viruses 
living in birds and mammals as natural hosts. The name indicates their ability 
to produce tumors (Greek poly- many, multiple; -oma, tumors), particularly in 
rodents and experimental models [46].
Seroprevalence in humans ranges from 20 to 90%, depending on the viral 
strain and patient age. It generally remains asymptomatic in the renourinary tract 
of healthy individuals, although may undergo periods of self-limiting transient 
asymptomatic activation with viruria and viremia, without causing disease [46]. 
However, in immunocompromised individuals, such as renal transplant recipi-
ents, it can be associated with various patterns of tissue injury, of which BK virus 
nephropathy is the most common.
Among approximately 18 polyomavirus strains, BK virus, JC virus, and simian 
virus (SV-40) have been considered to be pathogenic in humans. Infections with 
SV-40 were detected following the administration of contaminated polio vaccines 
in the late 1950s, without known clinical manifestation in humans [46].
BK virus was isolated in 1971 from a patient with ureteral stenosis after kidney 
transplantation and was named after the initials of the infected patient. Similarly, JC 
virus was named after a patient with progressive multifocal leukoencephalopathy. 
Both strains are characterized by productive viral infection with tissue injury, show-
ing specific tropism for the renourinary tract or central nervous system [46, 47].
Recent studies have indicated that BK virus may be involved in the tumorigen-
esis of bladder carcinoma in renal transplant recipients and salivary gland inflam-
mation and sclerosis in HIV patients [48, 49]. Trichodysplasia spinulosa-associated 
polyomavirus and Merkel cell carcinoma polyomavirus, recently detected new 
strains, may be related to proliferative lesions and neoplasms without productive 
viral replication [50].
3.1 BK nephropathy
PVN is a major causative agent in nephropathy after renal transplantation, 
affecting 1–10% of patients [51].
In the past, when immunosuppressive therapy was based mainly on cyclospo-
rine, only sporadic PVN cases were reported. Although modern immunosuppres-
sive drugs introduced after 1990 have enabled less rejection and improved allograft 
survival, they have been responsible for the occurrence of previously uncommon 
side effects, including PVN and hemorrhagic cystitis [47].
Before screening protocols for PV reactivation in renal transplant recipients 
were routinely used, PVN was usually diagnosed late after transplantation, in 
an advanced histologic stage, with chronic renal changes leading to allograft loss 
within 1 year in 50–90% of cases [4, 50]. Potential misdiagnosis of concurrent 
rejection resulting in increased immunosuppression might contribute to accelerated 
allograft failure.
3.2 Features of BKN
PVN is typically caused by the BK strain and only rarely by simultaneous 
activation of BK and JC viruses. The specific viral activation mechanisms remain 
unknown [47]. The transplant microenvironment may promote viral reactivation, 
because only sporadic detection of PV in native kidney of patients with other organ 
transplants or in immunodeficient patients has been reported [52, 53]. PVN also 
commonly occurs in patients with posttransplantation complications, including 
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delayed graft function and acute rejection. Other risk factors are male gender, older 
recipient age, diabetes, prolonged ureteral stent placement, smoldering subclinical 
graft inflammation, and/or abnormalities of dendritic cell and NK cell/T-cell acti-
vation. Relative over-immunosuppression by modern immunosuppressive drugs, 
though, is considered the main risk factor [47, 51, 54].
Polyomavirus infection represents serological or virological evidence of virus 
exposure without distinguishing among replicating, latent, and transforming 
patterns. Manifest viral disease is, however, defined as histological evidence of 
polyomavirus-mediated organ pathology and is mainly limited to immunocompro-
mised patients, such as transplant recipients [47, 55, 56].
Figure 6. 
Diagnosis of BK nephropathy: intranuclear viral inclusion bodies in tubular  epithelial cells (A, HE, 200x), 
intracellular virions of 40–50 nm in diameter by electron microscopy (B, electron micrograph), intranuclear 
expression of SV-40 antigen in tubular epithelial cells (C) and/or epithelial cells of Bowman’s capsule (D, both 
SV-40, 400x).
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Recognition of BKN is critical, since the proper therapy is reduction, rather than 
enhanced immunosuppression.
3.3 Diagnosis of BKN
In order to confirm intrarenal BKV replication, renal biopsy remains the gold 
standard for a definitive diagnosis of BKN [51]. A minimum of two cores including 
the medulla are recommended to make a correct diagnosis, since in the early stage, 
viral inclusions may be present only in the medulla [5, 51, 57]. However, charac-
teristic viral inclusion and tubular injury might be focally observed in the biopsy 
specimens, so PVN can be missed due to sampling error (Figure 6).
3.3.1 Morphological characteristics of BKN
BKN is morphologically characterized by intrarenal viral replication, mainly in 
tubular epithelial cell nuclei (intranuclear inclusions), causing tubular injury, shedding 
of tubular epithelial cells, and cell lysis (Figures 7 and 8). On immunofluorescence, 
focal immune complex-type granular deposition of IG along the tubular basement 
membrane is sometimes found, indicating BK infection (Figure 9), although the 
biologic and clinical significance of this finding needs further evaluation [5].
Viral replication in tubular epithelial cells can induce various nuclear changes: 
an amorphous ground-glass inclusion body (type 1), a central irregular inclusion 
body surrounded by a halo (type 2), finely granular nuclear alterations (type 3), 
and vesicular changes with coarsely clumped viral inclusions (type 4) (Figure 10). 
Figure 7. 
BK virus nephropathy. Virally induced tubular epithelial cell injury and lysis in cortex (A, HE, 200x) and 
medulla (B, HE, 100x). Intranuclear viral inclusion bodies are observed (arrow).
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In rare cases, the ascending PV infection can affect the parietal epithelial cells of 
Bowmanʼs capsule, mainly detected by immunohistochemistry (Figure 6).
Diagnostic confirmation can easily be achieved by immunohistochemistry 
(Figure 6) or immunofluorescence, with antibodies directed against the poly-
omavirus T antigen, VP capsid proteins, or detection of intracellular virions of 
40–50 nm in diameter by electron microscopy (Figure 11) [5, 57].
In early stages of PVN with focal and minimal tubular changes without 
tubular injury and characteristic intranuclear inclusions, a diagnosis can only be 
established by immunohistochemistry with antibody directed against SV-40-T 
antigen (Figure 12). Later in the course of the disease, many cases of PVN may 
show numerous infected cells and an inflammatory lymphocytic infiltrate with 
tubulitis mimicking acute T-cell-mediated rejection (Figure 13). Advanced dis-
ease, detected late after transplantation, often shows marked interstitial fibrosis/
tubular atrophy, while interstitial inflammation and viral replication may be 
variable (Figure 14).
3.4 Differential diagnosis of BKN
PVN must be differentiated from other rare viral infections, including CMV, 
herpes simplex virus, and adenovirus. CMV disease in transplant recipients is more 
frequent than BKN and usually affects the intestine, liver, or lungs but only rarely 
manifests as CMV reactivation in renal graft. Since the histological features of BKN 
Figure 8. 
Virally induced tubular epithelial cells with intranuclear inclusions, shedding of infected cells, tubular injury, 
and lysis (A,HE, 400x and B, HE, 200x).
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may overlap with other viral infections, specific immunohistochemical staining is 
a sensitive tool for differentiating among BK, CMV, adenovirus, or herpes simplex 
viral infection. The main histological features of common transplant kidney viral 
infection are shown in Table 2.
Figure 9. 
On immunofluorescence, focal immune complex-type granular deposition of IgG along the tubular basement 
membrane is sometimes found.
Figure 10. 
Various nuclear changes induced by viral replication: type 1, an amorphous ground-glass inclusion body (A); 
type 2, a central irregular inclusion body surrounded by nuclear halo (B); type 3, finely granular nuclear 
alteration (C); type 4, vesicular nuclear changes with coarsely clumped viral inclusions (D, all HE, 600x).
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Figure 11. 
Intranuclear viral inclusions in a tubular epithelial cell (A). Intranuclear virions measuring 40–50 nm in 
diameter (B, electron micrographs).
Figure 12. 
BKN grade 1. Early phase with only focal tubular injury.(A, HE, 100x) and  few SV-40 positive cells on 
immunohistochemistry (B, SV-40, 100x).
19
Viral Infections after Kidney Transplantation: CMV and BK
DOI: http://dx.doi.org/10.5772/intechopen.86043
However, the most important differential diagnosis, particularly in PVN after 
reduction of immunosuppression, remains T-cell-mediated acute rejection [6]. 
Careful correlations with clinical data, such as the presence of donor-specific 
antibodies, recent immunosuppression reduction, DNA viral load in the serum, 
and presence of decoy cells in the urine, provide additional information in order 
to make a correct diagnosis. Glomeruli and vessels must be carefully examined 
in order to exclude glomerulitis and vasculitis, which would strongly suggest 
concomitant rejection. C4d positivity and diffuse peritubular capillaritis outside 
the area of extensive interstitial inflammation, together with positive donor-
specific antibodies (DSA), are consistent with concomitant antibody-mediated 
rejection.
A diagnosis of PVN and concomitant T-cell-mediated rejection after immunosup-
pression reduction is challenging and needs careful correlation of biopsy findings with 
the dynamics of BK viremia. Focal interstitial inflammation in the context of stable 
graft function and recently cleared BK viremia should be interpreted as residual BKN, 
but the same histology findings detected beyond 3 months after BK clearance, accom-
panied by a rise in serum creatinine, might rather point toward acute rejection.
3.5 Course of BKN
The natural course of BKN remains to be elucidated. Some authors have 
reported that biopsies obtained after reduction of immunosuppression during 
Figure 13. 
BKN grade 2. Florid phase with severe interstitial inflammation and tubulitis in BK nephropathy, 
indistinguishable from acute rejection. There was no endarteritis (A, PAS, 200x).  Numerous BK-positive cells 
on immunohistochemistry were detected. (SV-40, 200×).
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decrease of the plasma viral load may show severe interstitial infiltrate and 
tubulitis reminiscent of T-cell-mediated acute rejection, but the outcome of renal 
grafts was good despite prolonged reduction of immunosuppression without 
corticosteroid administration [4, 6, 58, 59]. Such patients typically presented with 
a transient increase in serum creatinine, accompanied by a decrease in plasma 
viral load, which finally disappeared [59]. Moreover, serum creatinine returned 
to the baseline level after a few months. In subsequent biopsies, the virus was 
cleared from renal tissue, and inflammation resolved without the presence of 
marked interstitial fibrosis. These authors have suggested that such tubulointer-
stitial nephritis might be immune reconstitution-associated graft inflammation, 
enabling the resolution of PVN.
Figure 14. 
BKN grade 3. Moderate interstitial fibrosis/tubular atrophy and interstitial inflammation composed of CD3 
positive lymphocytes in areas of fibrosis (A, CD3 and PAS, 100x). Many tubules show viral replication  
(B, SV-40 antigen, 200x).
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The challenging concepts of immune reconstitution injury and extensive 
inflammation in resolving BKN after reducing immunosuppression need further 
investigation [6].
3.6 Clinical presentation and management of BKN
3.6.1 Clinical presentation and prognosis
Various studies have indicated that different extents of BKN in the transplant 
may predict the clinical presentation and outcome of the disease [58, 60, 61].
In order to provide optimal diagnostic and prognostic information of BKN, the Banff 
working group on BKN proposed three clinically significant disease grades based on the 
severity of polyomavirus replication and the degree of interstitial fibrosis [47, 62, 63]. 
BK virus replication was defined as the histologic viral load, estimated by the % of virally 
infected epithelial cells detected by immunohistochemistry. It ranged from scattered 
SV-40-positive cells in BKN grade 1 to numerous in grades 2 and 3 (Figures 12–14). In 
addition to SV-40-positive cells, grade 3 is characterized by interstitial fibrosis, which is 
responsible for irreversible tissue injury leading to graft failure [5, 47, 62].
Disease grade may reflect the time of the diagnosis: BKN grade 1 was generally diag-
nosed in the first 5 months after transplantation, usually presenting with normal renal 
function and associated with a favorable outcome in 85–90% of cases. In contrast, grade 
2 BKN was detected 6–12 months posttransplantation, characterized by elevated serum 
creatinine or acute graft injury leading to graft failure in 25% of cases. Finally, BKN 
grade 3 was usually detected more than 12 months after transplantation, also associated 
with worsening of kidney function and graft failure in 50% of cases (Table 3).
Since BKN has limited treatment options, the early detection of PVN has a major 
impact on the prognosis of the disease and therefore on allograft survival. Early 
diagnosis of PVN is difficult, because early BKN stage does not show any signs of 
systemic infection, proteinuria, or hematuria. Renal function may remain normal 
transiently, particularly when only the medulla is involved [5].
Polyomavirus Cytomegalovirus
Viral inclusions Type 1: an amorphous ground-
glass inclusion body
Type 2: a central irregular inclusion 
body surrounded by nuclear halo
Type 3: finely granular nuclear 
alteration
Type 4: finely granular nuclear 
alteration
Smudgy/ground-glass nuclear inclusions 
surrounded by typical halo-owl eye
Viral replication 
tubules
Yes Yes
Endothelial cells No Yes
Inflammatory cells No Yes
Acute tubular injury Rarely Rarely
Interstitial 
inflammation
Focal to diffuse Focal
Tubulitis Mild to severe Mild
Table 2. 
Histologic features of CMV and polyoma BK viral lesions in transplanted kidney.
Perioperative Care for Organ Transplant Recipient
22
3.6.2 Screening of PVN
To date, reduction of baseline immunosuppression remains the only potentially 
effective therapeutic strategy of BKN, but it is associated with an increased risk of 
rejection. It is considered that preemptive reduction of immunosuppression prior to 
the development of overt nephropathy might be beneficial [6, 51, 59]. Since unrec-
ognized BKN diagnosed late after transplantation causes chronic tissue injury and 
graft failure, the goal of screening protocols and classification schemes of BKN is to 
characterize early disease grades that respond to therapeutic intervention and may 
heal without progressing to chronic graft injury.
The first step of viral reactivation shown in almost all patients is character-
ized by the detection of characteristic polyomavirus inclusion-bearing cells in the 
urine—decoy cells (Figure 15). Initial viruria may be followed by detection of BK 
virus in plasma and onset of BKN after a 6–12-week window in some patients but 
only in a minority (Figure 16) [51].
Current guidelines recommend a urinary cytology test in order to detect urinary 
decoy cells initially and then a plasma test by PCR if urinary decoy cells are consis-
tently present [51]. While PVN is most commonly diagnosed in the first year after 
transplantation, urine screening at least every 3 months during the first 2 years and 
after antirejection treatment seems appropriate to cover the majority of PVN cases 
[51]. The cytology urine test is characterized by a high negative predictive value to 
rule out a diagnosis of BKN and reduce costs. In addition, a window between viral 
reactivation and BKN enables urine samples to be screened in time.
However, several studies have shown that only a variable number of patients 
with urinary shedding of virus progressed to BKN. Notably, BK viruria and even 
Figure 15. 
Decoy cells in urine screening test.
PVN disease 
grade
Viral load Interstitial 
fibrosis
Renal function Time of diagnosis 
after TX (months)
Favorable 
outcome (%)
Grade 1 Scattered 
SV-40-
positive cells
No Normal 4–5 85–90
Grade 2 Numerous Less than 
25%
Increased serum 
creatinine, renal 
failure
6–12 75
Grade 3 Numerous More than 
25%
Increased serum 
creatinine, acute 
renal failure
12 50
Table 3. 
Characteristics of different BKN grades regarding viral load, chronic tissue injury-interstitial fibrosis, renal 
function, time of diagnosis after transplantation, and outcome.
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viremia may represent transient asymptomatic BK activation or may originate from 
extrarenal sites, usually along the lower urinary tract. In patients without biopsy-
proven BKN, preemptive long-lasting reduction of immunosuppression could be 
potentially harmful due to increased risk of acute rejection [64].
3.6.3 Biomarkers of BKN
A plasma test by PCR detecting BK copies is currently the accepted biomarker 
for clinical application, although the exact range of viral load that would predict 
BKN cannot be defined. The majority of patients with more than 10,000 copies 
per ml DNA in 1 ml of plasma show BKN on renal biopsy, but some patients with 
hardly detectable BK virus copy numbers may have manifest BKN. Several studies 
have indicated that PCR-based BK viremia correlates only moderately well with the 
presence of BKN and severity of the intrarenal disease, ranging between 25 and 
75% (Figure 15) [6, 57].
Several biomarkers had been proposed in order to enable noninvasive diagnosis 
of definitive BKN without the risk of renal biopsy; these include heat shock pro-
tein 90alfa, CXCL9, neutrophil gelatinase-associated lipocalin, urinary exosomal 
biomarkers, urinary VP1, and urinary Haufen [65–67].
Polyomavirus-Haufen are tight cast-like three-dimensional viral aggregates, 
detected by negative staining electron microscopy of a voided urine sample. Since 
polyomavirus-Haufen admixed with uromodulin is formed in the tubular lumens, 
they might specifically predict intrarenal disease, comparable to renal biopsy [68]. 
Recent studies have indicated that the titer of polyomavirus-Haufen tightly cor-
relates with the degree of intrarenal polyomavirus replication, providing additional 
information on the severity of PVN [64]. The urinary polyomavirus-Haufen test 
may emerge as a sensitive and specific biomarker for intrarenal viral disease, with 
positive and negative predictive value higher than 90%. The limitations of this 
Figure 16. 
Type and prevalence of BK virus (BKV) infections in kidney transplant recipients.
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investigation include the relatively high cost, time-consuming procedure, and 
limited availability of electron microscopy in transplant centers.
BK virus VP1 mRNA and urinary exosomal miRNA biomarkers have been 
described as potential surrogate markers for the diagnosis of PVN, with high sen-
sitivity and specificity for BKN [66, 67]. Detection of additional urine biomarkers 
not only offers additional strategies for noninvasive PVN diagnosis but might also 
predict graft outcome.
3.6.4 Treatment of BKN
Management of PVN is still very limited. Reduction of the baseline immuno-
suppression, as the common therapeutic strategy, may be risky due to the pos-
sibility of acute rejection and may not be successful in all patients. Namely, some 
patients with BK viremia subsequently develop definitive BKN despite preemptive 
reduction of immunosuppression [4]. On the other hand, prolonged reduction 
of immunosuppression may be associated with clinical acute rejection rates of 
8–14% [5, 69]. Renal biopsy, although considered to be an invasive procedure, 
may provide additional information in order to diagnose concomitant vascular 
rejection.
Data concerning the frequency of concurrent PVN and rejection vary. Some 
authors consider inflammation to be part of immune reconstitution injury, with a 
very low risk of concomitant rejection, whereas others have diagnosed concurrent 
acute rejection in 10–15% of cases at the time of initial PVN diagnosis [6, 47, 63]. 
Additional corticosteroid treatment in patients with PVN and severe tubulointer-
stitial inflammation at the time of PVN diagnosis also remains controversial. Some 
authors believe that corticosteroid treatment interferes with efficient BK clearance 
from the graft although, on the other hand, it might decrease interstitial inflamma-
tion and subsequent interstitial fibrosis [59].
Biopsy-proven diagnosis of concurrent BKN and rejection reveals the therapeu-
tic dilemma concerning treatment strategy. In some individual cases, concomitant 
biopsy-proven T-cell-mediated rejection and PVN on low immunosuppression have 
been efficiently treated with transient pulse immunosuppressive therapy [70]. On 
surveillance kidney biopsy, BK was cleared from the tissue, interstitial inflamma-
tion disappeared, and serum creatinine returned to the baseline level.
Many of the therapeutic agents, including leflunomide, quinolone, and 
cidofovir, have been involved in BKN treatment with undetermined antipoly-
omavirus effect. It was recently shown that intravenous immunoglobulins’ (IV 
IGs) administration may be effective in the treatment of BK viremia and PVN 
in patients who have failed to respond to immunosuppression reduction and 
leflunomide therapy [71].
Successful resolution of BKN and BK clearance may be associated with the 
recipient’s antiviral cell-mediated immune response. Recently, novel laboratory-
based methods based on BK-directed cellular immunity and anti-BK T-cell 
phenotype have been introduced, such as ELISPOT assays, which might provide 
additional information in relation to the resolution of PVN [72–74].
4. Conclusions
KTRs receiving immunosuppressive regimes to prevent transplant rejection are 
at increased risk of opportunistic infections such as CMV and polyoma BK virus. In 
both viruses, reactivation of latent infection is the principal mechanism rather than 
de novo infection.
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While reactivation of CMV infection is usually present with systemic infection, 
including fever, leukopenia, organ dysfunction, and viremia without invading renal 
graft, the most harmful presentation of BK infection reactivation includes BKN 
directly affecting the transplanted kidney.
Both CMV and BK infections commonly appear in the first year after transplan-
tation, so screening protocols are very important in order to detect patients with 
increased risk of virus reactivation and early disease, and this should be started 
immediately after transplantation.
With systematically quantitative monitoring of CMV DNA in plasma, 
CMV viremia can be detected before the occurrence of symptomatic infection. 
Ganciclovir and valganciclovir are generally used to prevent or treat CMV.
For BKN screening, current guidelines recommend a urinary cytology test 
initially and then plasma DNA test by PCR if urinary decoy cells are consistently 
found.
The reduction of baseline immunosuppression is considered to be the common 
therapeutic strategy of BKN but is associated with increased risk of rejection. Since 
polyomavirus viruria and viremia can be observed without renal injury and BKN, 
a definite diagnosis of PVN must be confirmed by renal biopsy. In order to prevent 
BKN in viremic patients, preemptive reduction of immunosuppression prior to the 
development of overt nephropathy might be beneficial.
Careful detection and management of opportunistic infection enable better 
graft survival and quality of life in KTRs.
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